Arca
Skip to content
Tools
Tools

Pemphigus

Drug research and approvals for pemphigus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 19, 2026, 11 studies of pemphigus are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 7 open orphan designations naming it.

  • Recruiting worldwide: 11
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 11 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 4

Phase 3 7

Phase 2 9

Phase 1 or earlier 4

How its trials ended

63 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 20 whose ending is known, 25% met their primary endpoint, 10% missed it and 65% stopped early.

  • Completed, result not reported1625%
  • Status unknown1524%
  • Ongoing1219%
  • Stopped: sponsor or business decision610%
  • Met its primary endpoint58%
  • Stopped: other or unclear35%
  • Missed its primary endpoint23%
  • Stopped: enrollment or feasibility23%
  • Stopped: lack of efficacy12%
  • Stopped: funding12%

Trials authorized in Canada

Newest first; search them all in Canada trials
Feb 28, 2019A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of oral btk inhibitor PRN1008 in moderate to severe…Rilzabrutinib (PRN1008) / RituximabPrincipia Biopharma IncClosed
May 14, 2015"a randomized, double-blind, double-dummy, active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus mmf in patients with…Rituxan / CellceptRocheOngoing

FDA orphan designations

Approved first, then open designations, newest first
Jun 7, 2018Rituxan(r); MabThera(r)RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.Genentech, Inc.Approved
Aug 20, 2026Bispecific humanized IgG4 BCMA-directed CD3 T cell engager…Treatment of pemphigusOuro Medicines Ltd.Designated
Mar 14, 2026Resecabtagene autoleucelTreatment of pemphigus vulgarisCabaletta Bio, Inc.Designated
Oct 16, 2025AfamelanotideTreatment of pemphigusWanbangde Pharmaceutical Group Co., Ltd.Designated
Jan 28, 2020Autologous Desmoglein 3 (DSG3) Chimeric Autoantibody…Treatment of pemphigus vulgarisCabaletta Bio, Inc.Designated
May 14, 2014AfamelanotideTreatment of familial benign chronic pemphigus (Hailey-Hailey disease)Clinuvel, Inc.Designated
May 26, 2006Mycophenolate mofetilTreatment of pemphigus vulgarisHoffman-La Roche, Inc.Designated
Oct 26, 2004Desmoglein 3 synthetic peptide (PI-0824)Treatment of pemphigus vulgarisPeptimmune, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.